Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Global study finds stark differences in survival among children with cancer

Every year, more than 200,000 children under the age of 15 are diagnosed with cancer worldwide, and nearly 75,000 die from the disease.

15 Dec 2025

Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, existing options do not lead to favorable clinical outcomes in all patients.

12 Dec 2025

Researchers identify chromatin accessibility changes driving stem cell transformation in MDS

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and differentiation sustains healthy blood formation.

12 Dec 2025

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Small molecule discovery could open the door to new class of treatments for hard-to-treat cancers

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit a cancer-driving protein long considered impossible to target with drugs - a discovery that could open the door to a new class of treatments for leukemia and other hard-to-treat cancers.

9 Dec 2025

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing myelodysplastic syndrome (MDS), tend to develop it earlier, and often have more aggressive disease that is more likely to progress to acute myeloid leukemia.

9 Dec 2025

Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA circulating in the blood.

9 Dec 2025

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors.

9 Dec 2025

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare and aggressive form of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL).

8 Dec 2025

Timing of genetic mutation dictates childhood leukemia aggressiveness

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: it depends on when in development the mutation first occurs.

8 Dec 2025

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study.

7 Dec 2025

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor.

7 Dec 2025

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy.

7 Dec 2025

Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.

7 Dec 2025

Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation (TBI), the standard conditioning regimen used before hematopoietic cell transplantation.

7 Dec 2025

Many families of children with leukemia face significant financial hardship during treatment

Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL) – the most common pediatric cancer – develop serious financial difficulties during their child's treatment, including losing 25% or more of their household income and struggling to cover the costs of basic living expenses such as housing, food, and utilities.

7 Dec 2025

Black patients with AML experience earlier onset and poorer outcomes

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more than 20% more likely to die of any cause, according to an analysis of data conducted over a 34-year period and supported by the National Cancer Institute (NCI) is a component of the U.S. National Institutes of Health.

7 Dec 2025

New investment aims to accelerate treatments for low-grade brain tumors

Researchers focused on accelerating and testing new treatments for low-grade brain tumors are set to receive a transformative £2.8 million to drive their future work.

3 Dec 2025

A new generation of AML treatments brings hope for better survival

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates.

1 Dec 2025

Leukemia News and Research

Further Reading

Global study finds stark differences in survival among children with cancer

Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes

Researchers identify chromatin accessibility changes driving stem cell transformation in MDS

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

Small molecule discovery could open the door to new class of treatments for hard-to-treat cancers

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

Timing of genetic mutation dictates childhood leukemia aggressiveness

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia

Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL

Many families of children with leukemia face significant financial hardship during treatment

Black patients with AML experience earlier onset and poorer outcomes

New investment aims to accelerate treatments for low-grade brain tumors

A new generation of AML treatments brings hope for better survival

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News